Improved Gas Exchange After Tracheal Instillation of Surfactant in the Experimental Adult Respiratory Distress Syndrome

Lachmann, Burkhard; Fujiwara, Tetsuro; Chida, Shoichi; Morita, Tomoaki; Konishi, Mineo; K, Nakamura; Maeta, Haruo

doi:10.1097/00003246-198103000-00058

Cited by 15 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormalities in surfactant in lung lavage from patients with ALI/ARDS are well-documented [122][123][124][125][126][127][128][129], and exogenous surfactant therapy has a strong rationale based on extensive biophysical research showing that raising surfactant concentration can overcome inhibition by endogenous compounds present in injured lungs ( [52,53,[130][131][132] for review). In addition, the ability of exogenous surfactants to improve pulmonary mechanics and function has been established in multiple animal models of ALI/ARDS including acid aspiration [133][134][135], meconium aspiration [136][137][138][139], anti-lung serum [140], bacterial or endotoxin injury [141][142][143][144][145][146], vagotomy [147], hyperoxia [148][149][150][151][152], in vivo lung lavage [153][154][155][156][157][158], N-nitroso-Nmethylurethane (NNNMU) injury [159][160][161], and viral pneumonia [162,…”

Section: Exogenous Surfactant Therapy For Acute Phase Ali/ardsmentioning

confidence: 99%

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Raghavendran¹,

Pryhuber²,

Chess³

et al. 2008

CMC

111

View full text Add to dashboard Cite

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to single-agent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.

show abstract

Section: Exogenous Surfactant Therapy For Acute Phase Ali/ardsmentioning

confidence: 99%

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Raghavendran¹,

Pryhuber²,

Chess³

et al. 2008

CMC

111

View full text Add to dashboard Cite

show abstract

“…A variety of animal models of ARDS have been used to evaluate the efficacy of exogenous surfactant therapy. These animal models have established the ability of exogenous surfactant replacement to improve oxygenation, lung compliance, pulmonary mechanics, gas exchange and alveolar expansion, and to protect against histological damage [193][194][195][196][197][198][199][200].…”

Section: Adult Respiratory Distress Syndrome (Ards)mentioning

confidence: 99%

Surfactant Replacement Therapies in Children

Evans

Whitsett

1997

The Pediatric Lung

View full text Add to dashboard Cite

“…We found the lung lavage model (particu larly in small animals) useful for a variety of experimental purposes, especially for the testing of alternative surfactant preparations [14][15][16], as lung mechanics and arterial blood gases can be measured in up to 8…”

Section: Immature Rabbit Fetuses (Day 27)mentioning

confidence: 99%

Animal Studies of Surfactant Replacement Therapy

Lachmann¹

1989

Dev Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Before using surfactant preparations in animal experiments or in clinical trials, it is necessary that they fulfil specific in vivo requirements. But conclusive criteria for the effectiveness of a surfactant have not yet been defined. Thus, some standard levels for improvement of lung function, or threshold levels, must be established in standardized animal models with surfactant deficiency. The respiratory distress syndrome model of premature rabbit fetuses is the most sensitive model, followed by the surfactant deficiency model by lung lavage, while the model of viral pneumonia is the least sensitive when testing exogenous surfactant. With a less-effective exogenous surfactat, a small improvement in lung function in the rabbit fetus model and the lung lavage model can be observed, while in the viral pneumonia model almost no improvement occurred. Only a functional effective surfactant fulfilled all our criteria for functional improvement in lung function.

show abstract

Improved Gas Exchange After Tracheal Instillation of Surfactant in the Experimental Adult Respiratory Distress Syndrome

Cited by 15 publications

References 0 publications

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Surfactant Replacement Therapies in Children

Animal Studies of Surfactant Replacement Therapy

Contact Info

Product

Resources

About